Table III.
Contingencies of study outcomes and biologic class treatments
| Outcomes | Biologic classes |
||
|---|---|---|---|
| Anti-IgE | Anti–IL-5/IL-5Ra | Anti–IL-4Ra | |
| At least 1 exacerbation, pt.-mo. (%) | 14 (8.7) | 22 (7.6) | 5 (1.3) |
| Daily OCS use, pt.-mo. (%) | 87 (54) | 50 (17.2) | 30 (7.7) |
| Antifungal use, pt.-mo. (%) | 51 (31.7) | 24 (8.3) | 4 (1) |
| Total pt.-mo. | 161 | 290 | 390 |
| Daily OCS use, pt.-days (%) | 2,263 (42.7) | 1,011 (11.1) | 568 (4.1) |
| Antifungal use, pt.-days (%) | 1,163 (21.9) | 366 (4.1) | 82 (0.6) |
| Total pt.-days | 5293 | 8916 | 13997 |
Rows represent outcome measures, and columns represent biologic classes. Cells show the number of patient-months (top) and patient-days (bottom) of outcome variables while on each biologic class therapy.
pt.-mo., Patient-months.